Edward P Evans Foundation Archives
Blood cancer progression
Aug. 29, 2022—Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.
Impaired neutrophils in autoimmunity
Jan. 27, 2022—Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity.
Caught in a web: study reveals that immune cells cooperate to trap and kill bacteria
Sep. 10, 2021—Vanderbilt researchers have identified a new antibacterial mechanism that could inspire novel strategies for combating staph and other extracellular bacterial pathogens.
WIN for blocking cancer growth
Jan. 21, 2021—William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth.
One-two punch for cancer
Mar. 5, 2020—A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.
Grant bolsters research on myelodysplastic syndromes
Aug. 1, 2019—Michael Savona, MD, has received a competitive grant to develop therapies for patients with myelodysplastic syndromes.
Cell death pathway implicated in bone marrow failure
Jan. 31, 2019—Vanderbilt investigators have linked a specific form of programmed cell death to myelodysplastic syndrome, a type of bone marrow failure.
The yin and yang of COX-2
Oct. 2, 2015—New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.
